Kidney Week

Abstract: TH-PO483

Kidney Stone Incidence in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Session Information

• Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Genetic Diseases of the Kidneys

• 1201 Genetic Diseases of the Kidneys: Cystic

Authors

• Ostrow, Anna, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Anna Ostrow, MPH

• Gregory, Adriana, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Adriana Gregory, MS

• Kline, Timothy L., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Timothy L. Kline, MS, PhD

• Harris, Peter C., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Peter C. Harris, PhD

• Dahl, Neera K., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Neera K. Dahl, MD, PhD, FASN

• Erickson, Bradley J., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Bradley J. Erickson, MD, PhD

• Nowak, Kristen L., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Kristen L. Nowak, PhD, MPH

• Torres, Vicente E., Mayo Clinic Minnesota, Rochester, Minnesota, United States

Vicente E. Torres, MD, PhD

• Goldfarb, David S., New York University Grossman School of Medicine, New York, New York, United States

David S. Goldfarb, MD, FASN

• Gitomer, Berenice Y., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Berenice Y. Gitomer, PhD

• Chonchol, Michel, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Michel Chonchol, MD, FASN

Background

Nephrolithiasis, or kidney stone disease (KSD), is a common comorbidity in patients with ADPKD and is associated with an increased risk of more rapid decline in kidney function. However, incident rates of kidney stones within the ADPKD population have not been well examined. This study aimed to characterize the incidence of symptomatic kidney stone disease in an ADPKD patient population.

Methods

We focused on data from the Mayo Clinic repository (Olmstead County, MN). The observation window was defined as January 1^st, 1994, to December 31^st, 2023. Of 3,428 total ADPKD patients, 2,792 aged ≥ 18 years were included who had a recorded serum creatinine lab measurement between 1994 and 2023. Follow-up time per patient was calculated using the dates of their first and last serum creatinine measurements within the observation window, and initial stone diagnosis was defined as the earliest recorded date of KSD after 1993. Incidence rates were calculated per 1,000 person-years between males and females and across age groups.

Results

Of 2,792 eligible patients (1,256 males and 1,536 females), 545 had evidence of overall KSD (19.5%), while 380 had evidence of an initial diagnosis within this time period. The overall incidence rate was 27.9 per 1,000 person-years. KSD incidence rates remained similar in both males and females with ADPKD between 1994 and 2023 (Figure 1), with the highest overall rate observed in patients aged 18-29. We found the clearest increase in rates between 1994 and 2000, and the highest incidence per 1,000 person-years between 2000 and 2006.

Conclusion

In patients with ADPKD, a high incidence rate of KSD occurs in both males and females. Overall, the incidence rate of KSD has increased between 1994 and 2023.

Figure 1. KSD incidence rates by 5-year interval and age group, 1994-2023.

Funding

• NIDDK Support